Varian Exhibiting New HyperArc Technology for High Definition Radiotherapy and Radiosurgery

Varian Medical Systems today announced advances in its technology for high definition radiotherapy and radiosurgery. Varian is exhibiting its new HyperArc High Definition Radiotherapy (HDRT) technology at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting.
 
“This exciting new technology unlocks the potential of using highly non-coplanar treatment strategies to usher in a new era of precision in radiotherapy and radiosurgery for cancer patients,” said Kolleen Kennedy, president of Varian Oncology Systems. “HyperArc is the first step into our OnComand ecosystem that Varian introduced to the community last year. It is designed to automate and simplify sophisticated treatments such as Stereotactic Radiosurgery (SRS), and make them available to more cancer patients around the world.”
 
With HyperArc, clinicians should be able to deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue.
 
HyperArc is designed to capitalize on the unique capabilities of Varian’s TrueBeam and EDGE treatment platforms including the PerfectPitch couch. The HyperArc treatment delivery technology is currently FDA 510(k) pending. Treatment planning supporting HyperArc is a Works in Progress and is being developed to do virtual dry runs to evaluate treatment quality before the dose is delivered.
 
The company is aiming to make the HyperArc technology clinically available beginning in 2017. First generation HyperArc products will be designed for the radiosurgical treatment of brain metastases, with subsequent products being developed for other treatments throughout the body. Clinicians have been collaborating with Varian on the development and preliminary testing of this technology.
 
“In the testing we have done to date, we have found that the HyperArc technology showed a significant improvement in both the dose coverage to the targeted tumor and an associated reduction in the dose to the organs at risk,” said Garry Currie, head of Radiotherapy Physics at Beatson West of Scotland Cancer Centre in Glasgow, U.K. “We are excited about the potential of this technology and the impact it could make in the fight against cancer.”
 
Approximately 20 percent of newly diagnosed cancer patients will develop brain metastases, and for many SRS is recommended as a primary treatment option. HyperArc is designed to make it possible to easily target and eradicate isolated brain metastases and eliminate the need and complications with whole brain radiation.
 
The HyperArc technology is being exhibited in the Varian booth (#5063) at ASTRO from September 25-27th.